EU MDR Post-Market Clinical Follow-Up (PMCF): Requirements and Templates

What PMCF Is and Why It Is Mandatory Under EU MDR

Post-Market Clinical Follow-Up (PMCF) is the active, proactive, and systematic process of gathering clinical data on a CE-marked device during its commercial lifetime to update the clinical evaluation, identify emerging risks, and support the benefit-risk assessment. Under EU MDR 2017/745, PMCF is no longer optional or a good practice — it is a mandatory component of every manufacturer's post-market surveillance system for all device classes above Class I.

EU MDR Annex XIV Part B defines PMCF requirements. Article 61(11) requires that manufacturers conduct PMCF in accordance with Annex XIV Part B, and that the results be documented in a PMCF evaluation report that forms part of the clinical evaluation documentation and is updated as necessary.

The rationale for mandatory PMCF is regulatory logic: clinical evaluation under MDR is a living document, not a one-time submission exercise. As devices accumulate real-world use time, the clinical evidence base should grow, not remain static at the point of initial certification. PMCF is the mechanism through which post-market clinical data feeds back into the clinical evaluation and ultimately into the safety and performance assessment.

For manufacturers transitioning from MDD to MDR, PMCF requirements represent one of the most significant new obligations. Under MDD, post-market clinical follow-up was described in MEDDEV 2.12/2 as a supplement to clinical evaluation, but it was not rigidly enforced. Under MDR, a PMCF plan without genuine implementation is an audit finding, not a paper exercise.

PMCF Plan: Required Elements Under Annex XIV Part B

EU MDR Annex XIV Part B, Section 6.1 defines what a PMCF plan must contain. A compliant PMCF plan is not a generic post-market surveillance plan — it is a document specifically structured to describe how clinical data will be actively collected and analyzed after market introduction.

General methods and procedures: The PMCF plan must describe the general methods that will be used for PMCF, with justification for the suitability of these methods. Methods may include: post-market clinical investigations (PMCF studies), use of device registries, analysis of data from a relevant combination of sources, questionnaires and surveys of healthcare providers or patients, and systematic literature review of published data on the device or equivalent devices.

The choice of methods must be justified in relation to the device type, the risk class, and the clinical questions that need to be answered. A Class III implantable device with limited pre-market clinical data will require more active PMCF methods (e.g., a dedicated clinical follow-up study or registry participation) than a low-risk Class IIa device with extensive clinical literature.

Specific methods and procedures for implantable and Class III devices: For implantable devices and Class III devices, Annex XIV requires that PMCF plans include specific evaluation of implant survival and long-term outcomes where applicable. This is not satisfied by literature review alone for devices where the relevant clinical questions concern the specific device's long-term performance.

PMCF objectives: The plan must specify the clinical objectives that PMCF activities are intended to address. These objectives should be derived from the residual clinical questions identified in the current clinical evaluation. Objectives might include: confirming long-term safety of a specific material combination, obtaining data on performance in a patient subgroup that was underrepresented in pre-market studies, or monitoring an emerging signal identified in post-market surveillance.

Timelines: The plan must specify timelines for each PMCF activity, including when data will be collected, when it will be analyzed, and when the PMCF evaluation report will be updated.

PMCF Evaluation Report: What It Must Contain

The PMCF evaluation report is the output of the PMCF process — it documents what PMCF activities were conducted, what data was collected, what the findings were, and how those findings affect the clinical evaluation and benefit-risk assessment.

Annex XIV Part B, Section 6.2 defines the required content of the PMCF evaluation report. It must include: a summary of results from all PMCF activities described in the PMCF plan; an evaluation of the clinical relevance of the findings; conclusions about the clinical evidence, particularly whether the benefit-risk profile remains acceptable; and reference to any changes in the clinical evaluation or benefit-risk assessment resulting from PMCF findings.

Update frequency: The PMCF evaluation report must be updated following the completion of each PMCF activity, at minimum annually. For high-risk devices or devices with emerging safety signals, more frequent updates may be required. Notified Bodies will review PMCF evaluation report currency during surveillance audits — an outdated report is a common audit finding.

Connection to PSUR and clinical evaluation: The PMCF evaluation report is not a standalone document. Its findings must be incorporated into the Periodic Safety Update Report (PSUR) for Class IIa, IIb, and III devices, and must feed back into the clinical evaluation report to keep the clinical evidence assessment current. Many manufacturers maintain these documents in silos, which creates inconsistencies that Notified Bodies identify during review.

When PMCF reveals unexpected findings: If PMCF activities reveal safety signals or performance concerns not previously identified, the manufacturer must: update the benefit-risk assessment, update the risk management file, evaluate whether a Field Safety Corrective Action (FSCA) is required, and report to EUDAMED. PMCF is not just an academic documentation exercise — it is a real-time safety monitoring mechanism.

PMCF Study Design: Active Data Collection Approaches

When a PMCF plan determines that active data collection is required — through a PMCF study rather than literature review alone — the study must be designed appropriately for the clinical questions being addressed. PMCF studies are clinical investigations for the purpose of satisfying post-market clinical data obligations, and they are subject to relevant ethical and regulatory requirements.

Registries: Device registries are an established and efficient PMCF method for implantable devices and devices used in defined procedural settings. Participation in a national or international registry provides access to large-scale real-world performance data with standardized outcome reporting. Manufacturers should evaluate whether applicable registries exist for their device type and, if so, whether registry participation can serve as a primary PMCF method.

Post-market clinical investigations: For devices where no registry exists and where the PMCF objectives require structured prospective data collection, a post-market clinical investigation (PMCI) may be required. PMCIs are subject to Article 74 of EU MDR (for PMCIs intended to further characterize a device) or Article 75 (for PMCIs with interventional procedures). Both pathways require ethical committee approval and, in some cases, competent authority notification.

Systematic literature surveillance: For all devices, ongoing systematic literature review is a component of PMCF. This means regularly searching PubMed and other databases for publications on the device or equivalent devices, reviewing adverse event databases (EUDAMED, MAUDE, national vigilance databases), and reviewing complaint trend data. Literature surveillance must be documented — search strategies, search dates, inclusion/exclusion criteria, and findings must all be recorded.